(NASDAQ: XENE) Xenon Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.95%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.18%.
Xenon Pharmaceuticals's earnings in 2026 is -$409,195,000.On average, 20 Wall Street analysts forecast XENE's earnings for 2026 to be -$455,237,187, with the lowest XENE earnings forecast at -$467,874,863, and the highest XENE earnings forecast at -$412,830,762. On average, 20 Wall Street analysts forecast XENE's earnings for 2027 to be -$460,514,990, with the lowest XENE earnings forecast at -$521,969,928, and the highest XENE earnings forecast at -$193,196,662.
In 2028, XENE is forecast to generate -$351,646,977 in earnings, with the lowest earnings forecast at -$512,479,566 and the highest earnings forecast at -$215,566,802.